The pharmacy benefit manager says it has been able to negotiate a discount with Gilead enabling it to give both Harvoni and AbbVie’s Viekira Pak preferred formulary placement. Express Scripts also is expanding its indication-based oncology management initiative.
After making headlines with formulary placement in 2015 that excluded Gilead Sciences Inc.’s hepatitis C products, Express Scripts Holding Co. revealed Dec. 12 that it will include the fixed-dose combination pill, Harvoni, on its national preferred formulary for 2017.
The pharmacy benefit manager also announced that its indication-based oncology management program is expanding next year, including the addition of multiple myeloma among the covered indications.
Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.
Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.
